Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera

A retrospective, cross-sectional analysis demonstrated that 16.3% patients with polycythemia vera (PV) receiving hydroxyurea experienced thromboembolic events within the first year of starting treatment, which leads to increased inpatient admissions and emergency room visits and significantly higher annual healthcare costs for patients.

Journal of Managed Care & Specialty Pharmacy